Refractory thyroid carcinoma: which systemic treatment to use?

Abstract

The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on the tumor subtype. Still, many of these cancers will recur and may be treated with radioactive iodine or another surgery. It is unclear what treatment is best for cases of locally advanced or metastatic thyroid cancer that are refractory to radioactive iodine. Chemotherapy has a very low response rate. However, in the past few years, several systemic therapies, primarily targeted, have emerged to improve the overall survival of these patients. Alternative treatments are also of interest, namely peptide receptor radionuclide therapy or immunotherapy.

Keywords: PRRT; chemotherapy; mutations; peptide receptor radionuclide therapy; thyroid carcinoma; tyrosine kinase inhibitor.

Figure 1.

Intra-tumor signaling pathways in thyroid carcinoma.

Figure 2.

The 5-year survival of thyroid cancers according to stage.